Index of content:
Volume 11, Issue 4, December 2016
- Nanoparticle Interfaces
11(2016); http://dx.doi.org/10.1116/1.4944661View Description Hide Description
There is a continuous demand for sensitive and efficient cancerdrug delivery systems that, when administered at low concentrations, are capable of detecting early-stage pathological conditions and increasing patient survival without adverse side effects. Recent developments in the design of chitosan-based smart drug delivery nanocomplexes are able to respond to the distinctive features of the tumor microenvironment and have provided powerful tools for cancer targeted treatment. Due to its biocompatibility and pH-responsiveness, chitosan has emerged as a promising candidate for the formulation of novel, supramolecular multifunctional materials. This review will first present an overview of the characteristics of solid tumors and their microenvironment, with a particular emphasis on the role of pH as a key factor. In the second part of the review, the stimuli-responsive potential of chitosan-based micelles, current challenges in delivery, and strategies to improve therapeutic efficacy will be discussed.
11(2016); http://dx.doi.org/10.1116/1.4948265View Description Hide Description
Cardiovascular disease is the leading cause of death in the United States. Atherosclerosis is a major cause for cardiovascular diseases. Drugs that treat atherosclerosis usually act nonspecifically. To enhance drug delivery specificity, the authors developed a hydrophobically modified glycol chitosan (HGC) nanoparticle that can specifically target activated endothelial cells. The biocompatibility of these nanoparticles toward red blood cells and platelets was evaluated through hemolysis, platelet activation, platelet thrombogenicity, and platelet aggregation assays. The biocompatibility of these nanoparticles toward vascular endothelial cells was evaluated by their effects on endothelial cell growth, metabolic activity, and activation. The results demonstrated that HGC nanoparticles did not cause hemolysis, or affect platelet activation, thrombogenicity, and aggregation capability in vitro. The nanoparticles did not impair vascular endothelial cell growth or metabolic activities in vitro, and did not cause cell activation either. When conjugated with intercellular adhesion molecular 1 antibodies, HGC nanoparticles showed a significantly increased targeting specificity toward activated endothelial cells. These results suggested that HGC nanoparticles are likely compatible toward red blood cells, platelets, and endothelial cells, and they can be potentially used to identify activated endothelial cells at atherosclerotic lesion areas within the vasculature, and deliver therapeutic drugs.